Value
8.4/10data confidence 60%| Component | Sub-score |
|---|---|
| P/E | 9.8 |
| P/S | 6.9 |
| EV/EBITDA | 8.5 |
- ▸Attractively valued
ABUS · Why this verdict
Why Arbutus Biopharma (ABUS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score6.5/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The quality score of 7.9 is powered by a return on equity near 95%, margins near 84%, and a moat rated wide, with peer ranking calling the business best in class. Quality breakdown | Return on equity and margin metrics should hold near current elite levels and the Piotroski F-score should stay in the upper range over the next 12 months. | →Stable |
| CounterEarnings quality carries a flagged red flag, with free cash flow running at -56% of net income, meaning reported profitability is not fully converting to cash. | ||
Shares sit within 4.5% of the 52-week high and the resistance-based target has essentially been reached, producing a negative risk/reward ratio of -0.77 that failed the asymmetry gate outright. Reward-to-risk math | A new resistance level would need to open meaningfully more upside than the 7.0% stop distance for the risk/reward to turn favorable again over the next 12 months. | →Stable |
| CounterMomentum remains strong at 6.8, with the stock above its 200-day moving average and volume still accumulating, which could carry price through resistance to a higher target. | ||
The company has beaten estimates in three of the last four quarters, most recently by 4363.6%, driving the average trailing surprise sharply positive. Earnings | The beat streak should continue with at least one more beat over the next reported quarter for the pattern to hold over the next 12 months. | →Stable |
| CounterThe single in-line quarter in the trailing four came in below estimate at -21.76%, showing the streak is not unbroken. | ||
Despite strong quality metrics, the setup is capped at speculative, avoid-level position sizing because the roughly $1.0 billion market cap sits below institutional reach and the industry is inherently binary. Edge rationale | Market capitalization should grow well beyond the current small-cap level over the next 12 months for the sizing constraint to lift. | →Stable |
| CounterPeer ranking places the company in the top tier for value, quality, and growth simultaneously, an unusually strong combination for a name capped at speculative sizing. | ||
Risk notes flag an elevated put/call ratio of 3.00 and short interest of 13%, indicating options and short positioning are hedged bearishly even as the stock trades near its highs. Risk breakdown | The put/call ratio should fall back toward parity and short interest should ease over the next 12 months if bearish hedging is unwinding. | →Stable |
| CounterInsider activity has been neutral over the past 90 days, with $0 in net insider buying or selling, so the bearish options positioning is not being confirmed by insider signals in either direction. | ||
The quality score of 7.9 is powered by a return on equity near 95%, margins near 84%, and a moat rated wide, with peer ranking calling the business best in class.
→StableQuality breakdown
- Expectation
- Return on equity and margin metrics should hold near current elite levels and the Piotroski F-score should stay in the upper range over the next 12 months.
CounterEarnings quality carries a flagged red flag, with free cash flow running at -56% of net income, meaning reported profitability is not fully converting to cash.
Shares sit within 4.5% of the 52-week high and the resistance-based target has essentially been reached, producing a negative risk/reward ratio of -0.77 that failed the asymmetry gate outright.
→StableReward-to-risk math
- Expectation
- A new resistance level would need to open meaningfully more upside than the 7.0% stop distance for the risk/reward to turn favorable again over the next 12 months.
CounterMomentum remains strong at 6.8, with the stock above its 200-day moving average and volume still accumulating, which could carry price through resistance to a higher target.
The company has beaten estimates in three of the last four quarters, most recently by 4363.6%, driving the average trailing surprise sharply positive.
→StableEarnings
- Expectation
- The beat streak should continue with at least one more beat over the next reported quarter for the pattern to hold over the next 12 months.
CounterThe single in-line quarter in the trailing four came in below estimate at -21.76%, showing the streak is not unbroken.
Despite strong quality metrics, the setup is capped at speculative, avoid-level position sizing because the roughly $1.0 billion market cap sits below institutional reach and the industry is inherently binary.
→StableEdge rationale
- Expectation
- Market capitalization should grow well beyond the current small-cap level over the next 12 months for the sizing constraint to lift.
CounterPeer ranking places the company in the top tier for value, quality, and growth simultaneously, an unusually strong combination for a name capped at speculative sizing.
Risk notes flag an elevated put/call ratio of 3.00 and short interest of 13%, indicating options and short positioning are hedged bearishly even as the stock trades near its highs.
→StableRisk breakdown
- Expectation
- The put/call ratio should fall back toward parity and short interest should ease over the next 12 months if bearish hedging is unwinding.
CounterInsider activity has been neutral over the past 90 days, with $0 in net insider buying or selling, so the bearish options positioning is not being confirmed by insider signals in either direction.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Arbutus Biopharma combines elite quality and profitability metrics with a strong earnings beat streak, but shares sit near the resistance-based target with a negative risk/reward setup and a small-cap sizing constraint that together argue for trimming rather than adding.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 10.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 7.5 |
| Rule of 40 | 9.5 |
| Piotroski F | 6.7 |
- ▸Excellent ROE: 95%
- ▸Strong margins: 84%
- ▸Earnings quality RED FLAG: -56% FCF/NI
- ▸Wide economic moat
Growth
5.0/10data confidence 50%Momentum
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.0 |
| MACD | 7.6 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 3.8 |
- ▸Overbought (RSI 81)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 5.3 |
| erm sentiment | 5.0 |
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
8.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.1 |
| quality rank | 9.7 |
| growth rank | 10.0 |
- ▸Best in class
- ▸Attractive P/E vs peers
- ▸Superior ROE vs peers
Technical
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.1 |
| 52w position | 9.5 |
Risk (lower is worse)
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.4 |
| days to cover | 0.0 |
| volatility | 2.7 |
| put call | 9.3 |
| implied vol | 4.3 |
| max pain risk | 3.0 |
| beta | 9.3 |
| debt equity | 4.0 |
- ▸Above max pain $1
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/0M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- MOMENTUM:6.9>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:30d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.9=NEGATIVE
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.89
Upside
-13.4%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($1.0B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 5.5 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Value at 8.4) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-0.9=NEGATIVE) reinforce the read. Current asymmetry R:R is -0.89 — supplementary context, not the trigger for this path.
The strongest dimensions are Value at 8.4, Peer rank at 8.1, and Quality at 7.9; the weakest are Technical at 3.2, Risk (lower is worse) at 4.5, and Insider at 5.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.89 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Quality Compounder Metrics
Trip ifQuality score falls below 4.0 from the current 7.9.
- P2Negative Asymmetry Near Target
Trip ifRisk/reward ratio rises above 0 from the current -0.77.
- P3Earnings Beat Streak
Trip ifEarnings surprise falls below 0% in 2 consecutive quarters.
- P4Institutional Reach Caps Sizing
Trip ifMarket capitalization exceeds $2.0 billion, double the currently cited $1.0 billion level.
- P5Elevated Put Call Hedging
Trip ifPut/call ratio falls below 1.0 from the current 3.00.